---
title: "AstraZeneca Q2 profit beats estimates as cancer drug sales drive growth"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293899578.md"
description: "AstraZeneca reported Q2 earnings beating estimates, with core EPS rising to $2.63 and revenue reaching $15.38B, driven by strong sales of cancer drugs Enhertu, Imfinzi, and Tagrisso. Despite a disappointing trial for heart disease drug Wainua causing an 8% YTD stock drop, CEO Pascal Soriot reaffirmed FY2026 guidance, expressing confidence in long-term growth and the company's robust pipeline."
datetime: "2026-07-27T08:14:24.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293899578.md)
  - [en](https://longbridge.com/en/news/293899578.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293899578.md)
generator: "portal-rs"
---

# AstraZeneca Q2 profit beats estimates as cancer drug sales drive growth


### Related Stocks

- [AZN.US](https://longbridge.com/en/quote/AZN.US.md)
- [AZN.UK](https://longbridge.com/en/quote/AZN.UK.md)

## Related News & Research

- [AstraZeneca halts lung cancer trial of volrustomig in latest blow to pipeline](https://longbridge.com/en/news/296069146.md)
- [AstraZeneca Reports Mixed Lung Cancer Trial Outcomes From Three Pivotal Studies](https://longbridge.com/en/news/296114723.md)
- [AstraZeneca: Tagrisso Plus Orpathys Phase III Trial Shows PFS, OS Improvements In EGFRm Lung Cancer](https://longbridge.com/en/news/296071807.md)
- [Regeneron Stock (REGN) Buckling as Shareholders Sue Over Cancer Drug Claims](https://longbridge.com/en/news/296616209.md)
- [REG - AstraZeneca PLC - Update on eVOLVE-Lung02 Phase III trial](https://longbridge.com/en/news/296062318.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**